BioSpace News Archive

Key leadership team members previously led the development and commercialization of Zolgensma®, the first FDA-approved gene therapy for monogenic CNS disease Appoints former Chief Medical Officer of AveXis, Sukumar Nagendran, M.D., and former Chief Financial Officer of AveXis, Phillip Donenberg, to Board of Directors; Phillip Donenberg to serve as Audit Committee Chairman

SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead program expected to initiate first clinical studies in 2021 Rights to BOXR platform acquired for total of $11.5 million, including $8.1 million upfront and potential $3.4 million in milestones PRAGUE, Czech Republic an

Enigma Biomedical Group (EBG) today announced execution of a Master Development, License and Option Agreement and two Project Agreements to evaluate novel neuroimaging biomarkers from Janssen Pharmaceutica N.V. (Janssen), part of The Janssen Pharmaceutical Companies of Johnson & Johnson. These agreements permit EBG to evaluate Janssen’s PET ligands, and if such evaluation is favorable, grant to EBG an option to negotiate an

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the initiation of the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (“molluscum”).

Itamar Medical Ltd. announced that effective July 2020, Independence Blue Cross has removed their prior authorization requirement for home sleep apnea tests following an extensive dialog that included presentation of evidence.

New research from Parks Associates finds 25% of US broadband households plan to buy a connected health device in the next 12 months

Repertoire Immune Medicines, a clinical-stage biotechnology company focused on decoding and deploying the immune system across multiple major diseases, will present at Citi’s 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 9:30 am ET.

Erasca, a company whose mission is to erase cancer, today announced the completion of a $36 million extension of its Series B financing round, which brings the total round to $236 million.

VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).

Pear Therapeutics, Inc. announced findings today from two studies of an experimental precursor of Somryst™ (called SHUTi) that evaluated effectiveness to improve sleep outcomes and analyzed user journey data to predict intervention dropout, respectively.